Safety and tolerability

In the ADVANCE MPI Studies, a total 2015 patients received either Rapiscan or adenosine and were included in the safety analysis. Rapiscan was associated with a lower incidence of flushing, chest pain, chest discomfort and angina pectoris, and a higher incidence of headache, than adenosine (see table). 1,2

ADVANCE MPI 1 and ADVANCE MPI 2 Trials Adverse Events with Incdence = 5%
Adverse events with incidence ≥ 5%

In ADVANCE MPI 1 and ADVANCE MPI 2, the following pre-specified safety and tolerability endpoints comparing Rapiscan to adenosine achieved statistical significance: (1) a summed score of both the presence and severity of the symptom groups of flushing, chest pain, and dyspnoea was lower with Rapiscan (0.9 ± 0.03) than with adenosine (1.3 ± 0.05); and (2) the symptom groups of flushing (21% vs 32%), chest pain (28% vs 40%), and 'throat, neck or jaw pain' (7% vs 13%) were less frequent with Rapiscan; the incidence of headache (25% vs 16%) was more frequent with Rapiscan.

In clinical trials first degree AV block (PR prolongation > 220 msec) developed in 3% of patients within 2 hours of Rapiscan administration; transient second-degree AV block with one dropped beat was observed in one patient receiving Rapiscan. In post-marketing experience, third degree heart block and asystole have been reported within minutes of Rapiscan administration. In the ADVANCE MPI Trials, continuous electrocardiographic monitoring shows Rapiscan to be associated with less AV block than adenosine.


  1. Cerqueira MD, Nguyen P, Staehr P, et al, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist Rapiscan versus adenosine: integrated ADVANCE MPI trial results. J Am Coll Cardiol 2008;1:307-316
  2. Data on file. RPS EU Ltd, London (Source Table 2.7.4:9)